<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H5D11A31DEA9E4BA09DEC136B620DF78D" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 HR 6092 IH: Veteran’s Prostate Cancer Treatment and Research Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2020-03-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">116th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6092</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20200305">March 5, 2020</action-date><action-desc><sponsor name-id="D000628">Mr. Dunn</sponsor> (for himself and <cosponsor name-id="C001122">Mr. Cunningham</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HVR00">Committee on Veterans' Affairs</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Veterans Affairs to establish a national clinical pathway for prostate cancer, access to life-saving extending precision clinical trials and research, and for other purposes.</official-title></form><legis-body id="H0F247A81DFFB4C0980379A1D4C57949E" style="OLC"><section id="H511F8BEE0B1D4B0DB36F1E2700B5B7E3" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Veteran’s Prostate Cancer Treatment and Research Act</short-title></quote>.</text></section><section id="H4E8A156B2742403D982914EC52CF97D4"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress makes the following findings:</text><paragraph id="H43097A13C1E54F3190C82CB203317D0C"><enum>(1)</enum><text display-inline="yes-display-inline">Prostate cancer is the number one cancer diagnosed in the Veterans Health Administration.</text></paragraph><paragraph id="HDB9FFE6345E64DCB85D966406FBE7C35"><enum>(2)</enum><text>A 1996 report published by the National Academy of Sciences, Engineering, and Medicine established a link between prostate cancer and exposure to herbicides, such as Agent Orange.</text></paragraph><paragraph id="HC388DE0B10444D53AD182EC0D156ED28"><enum>(3)</enum><text>It is essential to acknowledge that due to these circumstances, certain veterans are made aware that they are high-risk individuals when it comes to the potential to develop prostate cancer.</text></paragraph><paragraph id="H2276DE07BFB0407A998249B055783A11"><enum>(4)</enum><text>In being designated as <quote>high risk</quote>, it is essential that veterans are proactive in seeking earlier preventative clinical services for the early detection and successful treatment of prostate cancer, whether that be through the Veterans Health Administration or through a community provider.</text></paragraph><paragraph id="HC87FFAD75B9740A6866E17514586E37C"><enum>(5)</enum><text display-inline="yes-display-inline">Clinical preventative services and initial detection are some of the most important components in the early detection of prostate cancer for veterans at high risk of prostate cancer.</text></paragraph><paragraph id="H459CFF940A6C4487BC98B58EB66FB3CB"><enum>(6)</enum><text display-inline="yes-display-inline">For veterans with prostate cancer, including prostate cancer that has metastasized, precision oncology, including biomarker-driven clinical trials and innovations underway through the Prostate Cancer Foundation and Department of Veterans Affairs partnership, represents one of the most promising areas of interventions, treatments, and cures for such veterans and their families.</text></paragraph></section><section id="H50BCFD1A92B348F2A1D18801D659CEF8"><enum>3.</enum><header>Department of Veterans Affairs treatment and research of prostate cancer</header><subsection id="H9A8CFAA46A8B4CD38DC1B59668F6B521"><enum>(a)</enum><header>Establishment of clinical pathway</header><paragraph id="H658C1D816CAE4234A42018DFB26B03AE"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 365 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall establish in the National Surgery Office of the Department of Veterans Affairs a national clinical pathway for all stages of prostate cancer, from early detection to end-of-life care including recommendations regarding the use of transformative innovations, research, and uniform clinical data.</text></paragraph><paragraph id="HFCBA0A8AAFDB4687849BFA5583F36824"><enum>(2)</enum><header>Elements</header><text>The national clinical pathway established under this subsection shall include the following elements:</text><subparagraph id="HCE3B8F383C334DD78866DB8457927DB9"><enum>(A)</enum><text display-inline="yes-display-inline">A multi-disciplinary plan for the early detection, diagnosis, and treatment of prostate cancer that includes, as appropriate, both Department medical facilities and community-based partners and providers and research centers specializing in prostate cancer, especially such centers that have entered into partnerships with the Department.</text></subparagraph><subparagraph id="H37CDD49612A244B4925008D7EC3B82D6"><enum>(B)</enum><text display-inline="yes-display-inline">A suggested, but not mandatory, protocol for screening, diagnosis, and treatment or care for subpopulations with evidence-based risk factors (including race, ethnicity, socioeconomic status, geographic location, exposure risks, and genetic risks, including family history).</text></subparagraph><subparagraph id="HFD71568FADF043E4AFABA46476A18E4F"><enum>(C)</enum><text>A suggested treatment protocol timeframe for each point of care based on severity and stage of cancer.</text></subparagraph></paragraph><paragraph id="H70E2D3E5ED60491AAF717514228F37BC"><enum>(3)</enum><header>Public comment period</header><text display-inline="yes-display-inline">Upon the establishment of a proposed clinical pathway as required under this subsection, the Secretary shall publish the proposed clinical pathway in the Federal Register and provide for a 45-day period for public comments. The Secretary—</text><subparagraph id="H7A8825F1E7A54DA39FEDF8525DD69FCE"><enum>(A)</enum><text>may make any such public comments publicly available; and</text></subparagraph><subparagraph id="H2A0E5D6CDCB54E64BF69779A4E68B4FC"><enum>(B)</enum><text>make changes to the proposed clinical pathway in response to any such comments received using the same process and criteria used to establish the proposed clinical pathway.</text></subparagraph></paragraph><paragraph id="HBC56544F8D7147A19D7F3B4BDE446F12"><enum>(4)</enum><header>Collaboration and coordination</header><text>In establishing the clinical pathway required under this section, the Secretary shall—</text><subparagraph id="H76D102C2699B4E6D8F8D5519CB6F65D9"><enum>(A)</enum><text display-inline="yes-display-inline">provide for consideration of other clinical pathways and research findings of other departments and agencies, including guidelines that are widely recognized and guidelines that are used as the standard for clinical policy in oncology care, such as National Comprehensive Cancer Network guidelines; and</text></subparagraph><subparagraph id="H42F724B1FC7244F1893D122C3FA0D2A7"><enum>(B)</enum><text>collaborate and coordinate with—</text><clause id="H2B3DF83E89574F53957C60BFC98113E3"><enum>(i)</enum><text>the National Institutes of Health;</text></clause><clause id="H24AA1F5FD755416D916CDF0257931E9E"><enum>(ii)</enum><text>the National Cancer Institute;</text></clause><clause id="HD7105B8A6A934E5283C88572CA23E664"><enum>(iii)</enum><text>the National Institute on Minority Health and Health Disparities;</text></clause><clause id="H4BC6C2380B704DB2BD93E0BE2CC578B2"><enum>(iv)</enum><text display-inline="yes-display-inline">other Institutes and Centers as the Secretary determines necessary;</text></clause><clause id="HCB9301E8EFF2413DBB5482F67A795EF2"><enum>(v)</enum><text display-inline="yes-display-inline">the Centers for Disease Control and Prevention;</text></clause><clause id="HF7BF36A9669E4C7D8E75406498391E00"><enum>(vi)</enum><text>the Department of Defense;</text></clause><clause id="H788842B211274C4AA6123EB09DDEE7B3"><enum>(vii)</enum><text>the Centers for Medicare and Medicaid Services;</text></clause><clause id="HB9F3D9B39DBD4829A66AF07258EE2A87"><enum>(viii)</enum><text>the Patient-Centered Outcomes Research Institute; and</text></clause><clause id="HC2064B81F1CB4432B730665D73C4FB33"><enum>(ix)</enum><text>the Food and Drug Administration.</text></clause></subparagraph></paragraph><paragraph id="H69D404935C5843D68CF5C6BB240D2B7B"><enum>(5)</enum><header>Publication</header><text>The Secretary shall—</text><subparagraph id="H7F927407259A45CDA2BEFAC9431ADAFE"><enum>(A)</enum><text>publish the clinical pathway established under this subsection on a publicly available Department website; and</text></subparagraph><subparagraph id="HF9809DF7207E477B90351470BD0F9785"><enum>(B)</enum><text display-inline="yes-display-inline">regularly update the clinical pathway as needed by review of the medical literature and available evidence-based guidelines at least annually, in accordance with the criteria under paragraph (2).</text></subparagraph></paragraph></subsection><subsection id="H5A93738CDEC44C1EBAE5459674259618"><enum>(b)</enum><header>Development of national cancer of the prostate clinical care implementation program</header><paragraph id="H62D9CC65415F4C33AB6C8243B9A0942E"><enum>(1)</enum><header>Establishment</header><text display-inline="yes-display-inline">Not later than 90 days after the date of the enactment of this Act, the Secretary shall submit to Congress a plan to establish a comprehensive prostate cancer program.</text></paragraph><paragraph id="HDB66D1C8C5F1473E9E0D8CCE533BA2B6"><enum>(2)</enum><header>Program requirements</header><text display-inline="yes-display-inline">The com­pre­hen­sive prostate cancer program shall—</text><subparagraph id="H456D6DF212B841F9B79B45F99236498D"><enum>(A)</enum><text>be multidisciplinary and include the authority to work across clinical care lines, specialties, and the organizational divisions of the Veterans Health Administration;</text></subparagraph><subparagraph id="H8A193939E59A4F5F8741BBF6F365E682"><enum>(B)</enum><text>receive direct oversight from the Deputy Undersecretary for Health of the Department of Veterans Affairs;</text></subparagraph><subparagraph id="H6257C0A35A914DCFB169C0304EF756F0"><enum>(C)</enum><text>include a yearly program implementation evaluation to facilitate replication for other disease states or in other healthcare institutions;</text></subparagraph><subparagraph id="H3C6A34A0A4B7416DA13FDF103CAEEC00"><enum>(D)</enum><text>be metric driven and include the development of quarterly reports on the quality of prostate cancer care, which shall be provided to the leadership of the Department, medical centers, and providers and made publicly available in an electronic form;</text></subparagraph><subparagraph id="HB01396237EDB413BA56E06E53344E9B0"><enum>(E)</enum><text>made available as national decision support tools in the electronic medical record;</text></subparagraph><subparagraph id="H2FB5B61A510F4A9881EC1AF6C1401D16"><enum>(F)</enum><text>include an education plan for patients and providers; and</text></subparagraph><subparagraph id="HBE25253E2EAF4955ADF243E054696776"><enum>(G)</enum><text>be funded appropriately to accomplish the objectives of this Act.</text></subparagraph></paragraph><paragraph id="H66CC979865B042E9995556FA2945C9A2"><enum>(3)</enum><header>Program implementation evaluation</header><text display-inline="yes-display-inline">The Secretary shall establish a program evaluation tool as an integral component to learn best practices of multidisciplinary disease-based implementation and to inform the Department and Congress regarding further use of the disease specific model of care delivery.</text></paragraph><paragraph id="H254C3EBFF6E14D4C8231ED544BD324A6"><enum>(4)</enum><header>Prostate cancer research</header><text>The Secretary shall submit to Congress a plan that provides for continual funding through the Office of Research and Development of the Department of Veterans Affairs for supporting prostate cancer research designed to position the Department as a national resource for quality reporting metrics, practice-based evidence, comparative effectiveness, precision oncology, and clinical trials in prostate cancer.</text></paragraph><paragraph id="H0CC45FCE8E714F738D58FC39D9C273D6"><enum>(5)</enum><header>Prostate cancer real time registry program</header><text display-inline="yes-display-inline">The Secretary, in collaboration with data stewards of the Department of Veterans Affairs, scientists, and the heads of other Departments, agencies, and non-governmental organizations, such as foundations and non-profit organizations focused on prostate cancer research and care, shall establish a real-time, actionable, national prostate cancer registry. Such registry shall be designed—</text><subparagraph id="H48E51D7E36F84197A8F1DDCE1C839C9D"><enum>(A)</enum><text display-inline="yes-display-inline">to establish a systematic and standardized database that enables intra-agency collaboration by which to track veteran patient progress, enable population management programs, facilitate best outcomes, and encourage future research and further development of clinical pathways, including patient access to precision resources and treatments and access to life-extending precision clinical trials;</text></subparagraph><subparagraph id="H3A35E6E7D50942BAADF25BFBC73D7F62"><enum>(B)</enum><text>to employ novel methods of structuring data, including natural language processing, artificial intelligence, structured data clinical notes, patient reported outcome instruments, and other tools, to ensure that all clinically meaningful data is included; and</text></subparagraph><subparagraph id="H2C5C9633AE54451A9FC021DE61664C23"><enum>(C)</enum><text display-inline="yes-display-inline">to be accessible to—</text><clause id="HE91ACE00792D469D97491C64BE90A65B"><enum>(i)</enum><text>clinicians treating veterans diagnosed with prostate cancer and being treated for prostate cancer in conjunction with Department medical facilities; and</text></clause><clause id="H99213A08CEA3448FA5FF52CAD9F4B6F2"><enum>(ii)</enum><text>researchers.</text></clause></subparagraph></paragraph></subsection><subsection id="HA0A6D70905F242C9B8303218DF0BAEDA"><enum>(c)</enum><header>Clinical pathway defined</header><text display-inline="yes-display-inline">In this section, the term <quote>clinical pathway</quote> means a health care management tool designed around research and evidence-backed practices that provides direction for the clinical care and treatment of a specific episode of a condition or ailment. </text></subsection></section></legis-body></bill> 

